



Life Sciences Financing Summary Europe


February 2016

Curevac collected the highest private financing round in November, raising EUR 100m in a private placement which made the month of November the 4th best month in 2015. The private financing raised by Curevac is the 4th highest private financing round raised by European Biotech companies (Therapeutic and Diagnostics) in 2015, behind Medimmune (EUR 417m), Immunocore (EUR 291m) and Mereo Biopharma (EUR 108m).

The total value of private financing for European Biotech companies (Therapeutics and Diagnostics) during the month of November amounted to EUR 229m which represents a 60% increase compared to the EUR 143m raised the previous month. In the month of December EUR 76m was raised to end the year on low note. To sum up the year of 2015, there has been a lot of variation from month to month, both in terms of total financing value and number of financing rounds. In April of 2015 EUR 538m was raised which is well above the monthly average of EUR 186m and significantly higher than the year low EUR 14m raised in February.

Continue reading below to learn more about the financing highlights of November and December 2015 in the European Life Science industry.

Europe - Biotech Therapeutic Financing Rounds



Source: Biotechgate.com

*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



Selected financing highlights: companies raising funds

November 2015

CureVac raises USD 110m in a private placement

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, announced on the 3rd of November 2015 that it has raised about USD 110m (EUR 100m) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. This new financing round was led by Baillie Gifford, adding to the approximately USD 220m CureVac has raised since its founding in 2000. The new investors, Baillie Gifford, Chartwave Limited, Coppel family, Elma Investments Ltd and Sigma Group, join existing investors dievini Hopp BioTech holding GmbH & Co. KG of Dietmar Hopp and the Bill & Melinda Gates Foundation. Proceeds from the financing round will be used to further develop CureVac's clinical pipeline of natural, chemically unmodified mRNA therapeutic and prophylactic product candidates. The new capital will also fund research and clinical development to expand CureVac's proprietary mRNA platform technology. (Source: Press release)

ObsEva Closes CHF 60m (EUR 56m) in Series B Financing

ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced on the 23rd of November 2015 the closing of a CHF 60m (EUR 56m) Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise Associates (NEA), OrbiMed, Rock Springs Capital as well as existing investors Sofinnova Partners, which seeded the company, Sofinnova Ventures, Novo Ventures and MS Ventures. The proceeds will support continued progress in ObsEva's late-stage pipeline of novel, oral treatments for women's reproductive health conditions. (Source: Press release)

Selected financing highlights – investors in November, December 2015

The following investors have made investments into European Life Science companies through November and December 2015:

- Abingworth
- Aglaia Oncology Fund II
- Baillie Gifford
- Banc de Sabadell
- Caixa Capital Risc
- Chartwave Limited
- Coppel Family
- Eix Technova
- Fouriertransform
- HBM Healthcare Investments
- hVIVO plc
- IFEM
- Imperial Innovations Group plc
- Johnson & Johnson Innovation JJDC, Inc
- Kurma Partners
- Life Sciences Partners
- MS Ventures
- New Enterprise Associates (NEA)
- Northview




- Novo Seeds
- Novo Ventures
- OrbiMed
- Rock Springs Capital
- SEB Venture Capital
- Sigma Group
- Sofinnova Partners
- SV Life Sciences
- Syncona
- VI Partners

Quarterly biotech equity financing breakdown by investment size (therapeutics & diagnostics)

In the fourth quarter of 2015, 43% of the financing rounds of Biotech companies (Therapeutics and Diagnostics) were in the smallest investment segment, those less than EUR 5m. This is very much in line with the year average of 45% which has been fairly consistent throughout the year. The second most frequent investment size in the fourth quarter was the EUR 15m to EUR 30m segment, accounting for 22% of all financing rounds. Compared to the third quarter of 2015, smaller sized investments gained relative importance compared to the larger sized investment segments. As one can see in the graph below, the three largest investment segments decreased in the fourth quarter compared the previous quarter.

Investment Size as % of Total - Biotechs T&D (Europe)



The graph above shows the proportion of financing rounds by investment size in the therapeutics and diagnostics category per quarter, including only private companies.

November, December 2015 financing rounds summary

Source: Biotechgate – www.biotechgate.com

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Cebiotex	Biotechnology / R&D Services	0.3	Private / independent	Spain
Specific Pig S.L.	Biotechnology / R&D Services	0.2	Private / independent	Spain
Transmural Biotech	Medical Technology	0.2	Private / independent	Spain
usMIMA	Medical Technology	0.4	Private / independent	Spain
Agendia NV	Biotechnology - Therapeutics and Diagnostics	6.2	Publicly listed on stock exchange	Netherlands
Xeltis AG	Medical Technology	30.0	Publicly listed on stock exchange	Switzerland
Iproteos S.L.	Biotechnology - Therapeutics and Diagnostics	0.2	Publicly listed on stock exchange	Spain
Inthera Bioscience	Biotechnology - Therapeutics and Diagnostics	3.4	Private / independent	Switzerland
Freeline Therapeutics	Biotechnology - Therapeutics and Diagnostics	34.4	Private / independent	United Kingdom
ERYTECH Pharma	Biotechnology - Therapeutics and Diagnostics	23.3	Private / independent	France
APD Advanced Perfusion Diagnostics	Medical Technology	1.6	Private / independent	France
Athera Biotechnologies AB	Biotechnology - Therapeutics and Diagnostics	2.6	Private / independent	Sweden
Kesios Therapeutics Ltd.	Biotechnology - Therapeutics and Diagnostics	26.2	Private / independent	United Kingdom
Santhera Pharmaceuticals (Schweiz) AG	Biotechnology - Therapeutics and Diagnostics	50.6	Private / independent	Switzerland
amcure GmbH	Biotechnology - Therapeutics and Diagnostics	1.9	Private / independent	Germany
Gene Predictis SA	Biotechnology / R&D Services	0.5	Private / independent	Switzerland
Chronos Therapeutics	Biotechnology - Therapeutics and Diagnostics	0.8	Private / independent	United Kingdom
Newron Pharmaceuticals S.p.A.	Biotechnology - Therapeutics and Diagnostics	5.4	Publicly listed on stock exchange	Italy
Alzinova AB	Pharma	1.8	Publicly listed on stock exchange	Sweden
Horizon Discovery	Biotechnology / R&D Services	3.1	Private / independent	United Kingdom
Magnisense SARL	Biotechnology / R&D Services	5.5	Private / independent	France
ObsEva SA	Biotechnology - Therapeutics and Diagnostics	55.9	Publicly listed on stock exchange	Switzerland
Wandercraft	Medical Technology	4.0	Publicly listed on stock exchange	France
Carbios	Biotechnology - other	1.6	Publicly listed on stock exchange	France
Faron Pharmaceuticals Ltd.	Biotechnology - Therapeutics and Diagnostics	10.0	Private / independent	Finland
Cortrium ApS	Medical Technology	1.6	Publicly listed on stock exchange	Denmark

Bactiguard AB	Medical Technology	14.0	Private / independent	Sweden
Recipharm AB	Biotechnology / R&D Services	25.0	Private / independent	Sweden
NightstaRx Ltd.	Biotechnology - Therapeutics and Diagnostics	32.6	Private / independent	United Kingdom
OSSDSIGN AB	Medical Technology	10.0	Publicly listed on stock exchange	Sweden
Oasmia Pharmaceutical AB	Biotechnology - Therapeutics and Diagnostics	0.0	Private / independent	Sweden
Mind the Byte, S.L.	Biotechnology / R&D Services	0.2	Private / independent	Spain
CureVac GmbH	Biotechnology - Therapeutics and Diagnostics	102.5	Private / independent	Germany
ElsaLys Biotech	Biotechnology - Therapeutics and Diagnostics	2.7	Publicly listed on stock exchange	France
DNA Electronics Ltd	Biotechnology / R&D Services	35.4	Private / independent	United Kingdom
OMEICOS Therapeutics	Biotechnology - Therapeutics and Diagnostics	1.7	Publicly listed on stock exchange	Germany
TiGenix NV	Biotechnology - Therapeutics and Diagnostics	5.4	Private / independent	Belgium
PrEP Biopharm	Biotechnology - Therapeutics and Diagnostics	29.7	Private / independent	United Kingdom
Hercules Pharmaceuticals BV	Biotechnology - Therapeutics and Diagnostics	3.5	Publicly listed on stock exchange	Netherlands

About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60
Web: www.venturevaluation.com
Email: info@venturevaluation.com

Copyright © 2016 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com